Agile Sciences and Calvert Research Announce Strategic Collaboration

Share Article

Agreement to Advance Pharmaceutical Applications for Agile Sciences’ Technology

We are very pleased to be working with Agile Sciences to evaluate the in vivo properties of the Agilyte™ compounds, which have the potential to revolutionize the treatment of life-threatening, drug resistant bacterial infections.

Agile Sciences, Inc. and Calvert Research, LLC, a business unit of Calvert Holdings, Inc., announced today that they have signed a strategic Research Collaboration to support the preclinical evaluation of Agile Sciences’ proprietary Agilyte™ small molecule compound library. The Agilyte™ compounds were created by co-founders Dr. Christian Melander and Dr. John Cavanagh at North Carolina State University (“NCSU”) and are designed to treat a wide range of antibiotic resistant bacterial infections. Rights to develop and commercialize these novel small molecule compounds were exclusively licensed to Agile Sciences by NCSU in 2007.

Hospital acquired bacterial infections are responsible for an estimated 100,000 deaths in the United States each year. Many of these new infections are resistant to multiple conventional antibiotics, and few new treatment options are being developed. In laboratory studies, Agilyte™ compounds have been shown to overcome antibiotic resistance in many different multi-drug resistant bacterial strains through a new mechanism which re-sensitizes these drug resistant bacteria to conventional antibiotics.

Under the terms of the Research Collaboration, Calvert Research will invest its management expertise and extensive preclinical development resources via its CRO affiliate, Calvert Laboratories, Inc., to test the ability of selected Agilyte™ compounds to successfully treat certain drug resistant bacterial infections (such as Methicillin Resistant Staphylococcus aureus, or “MRSA”) in mouse models. Calvert Research and Calvert Laboratories may also evaluate the in vivo safety and pharmacology profile of Agilyte™ compounds to determine their suitability for further pharmaceutical development. Based on the Research Collaboration study results, Agile Sciences and Calvert may elect to create and jointly own a new corporate entity that would hold the product development and commercialization rights to the Agilyte™ compound library for all human therapeutic and diagnostic uses.

Agile Sciences’ Chief Executive Officer, Mr. Keith Stoneback, stated, “This Collaboration leverages the impressive preclinical drug development capabilities of Calvert Research and facilitates Agile Sciences’ ability to more effectively advance the promise of our technology in human therapeutic applications”.

“We are very pleased to be working with Agile Sciences to evaluate the in vivo properties of the Agilyte™ compounds, which have the potential to revolutionize the treatment of life-threatening, drug resistant bacterial infections” commented Michael A. Recny, Ph.D., President of Calvert Research. “Our investment in this Collaboration represents another key example of our strategy to utilize our extensive drug development expertise and capabilities to help emerging biopharmaceutical companies create substantial value by advancing their discovery stage drug candidates closer to human testing.”

About Agile Sciences:
Agile Sciences is headquartered on North Carolina State University's Centennial Campus. The company was founded in 2007 to provide commercial solutions to those industries plagued by the effects of biofilms. The company's proprietary Agilyte™ compounds have been shown to be effective in overcoming bacterial resistance mechanisms. For additional information, please visit: http://www.Agilesci.com.

About Calvert Research:
Calvert Research, a business unit of Calvert Holdings of Cary, N.C., is pioneering a new way to work with early stage biopharmaceutical companies and academic institutions to help them advance their novel drug candidates from a promising discovery to the first stage of human testing. Calvert Research leverages its extensive drug development expertise by combining it with a wide range of preclinical services offered by its CRO affiliate, Calvert Laboratories, to design and execute customized, risk-sharing drug development partnership programs with its corporate and academic partners. For more information, please visit http://calvert-research.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Tippett

Jeff Tippett
Visit website